SGRY250117P50000
- 17.80
- 0.000.00%
Surgery Partners Newsroom
These 4 Measures Indicate That Surgery Partners (NASDAQ:SGRY) Is Using Debt Extensively
U.S. Healthcare Execs Turn More Bullish for 2025: Deloitte
Premier Plastic Surgery Partners Reveals the Top 5 Trends in Aesthetic Medicine for 2025
Surgery Partners Selloff Seen as Excessive -- Market Talk
Benchmark Co. Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $40
Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Liquidia Technologies (LQDA)
Express News | Surgery Partners Inc : Benchmark Cuts Target Price to $40 From $50
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $28
U.S. Healthcare Spending Climbs 7.5% in 2023
Investors in Surgery Partners (NASDAQ:SGRY) Have Unfortunately Lost 53% Over the Last Three Years
Worst Performing Stocks for Tax Loss Selling – Wolfe
BofA Securities Initiates Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $30
JPMorgan Adjusts Surgery Partners Price Target to $28 From $38, Maintains Neutral Rating
Surgery Partners, Inc. (NASDAQ:SGRY) Is Expected To Breakeven In The Near Future
Surgery Partners Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $35
Express News | Surgery Partners Inc : RBC Cuts Target Price to $35 From $49
Macquarie Maintains Surgery Partners(SGRY.US) With Buy Rating
Overreaction to Selloff: Surgery Partners' Undervalued Opportunity Amidst Strong Fundamentals
TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $32